{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:40:45Z","timestamp":1794980445585,"version":"4.9.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["No 101034420"],"award-info":[{"award-number":["No 101034420"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Antimicrob Resist Infect Control"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>In the fight against antimicrobial resistance, mathematical transmission models have been shown as a valuable tool to guide intervention strategies in public health.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>This review investigates the persistence of modelling gaps identified in earlier studies. It expands the scope to include a broader range of control measures, such as monoclonal antibodies, and examines the impact of secondary infections.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This review was conducted according to the PRISMA guidelines. Gaps in model focus areas, dynamics, and reporting were identified and described. The TRACE paradigm was applied to selected models to discuss model development and documentation to guide future modelling efforts.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We identified 170 transmission studies from 2010 to May 2022; <jats:italic>Mycobacterium tuberculosis<\/jats:italic> (<jats:italic>n<\/jats:italic>\u2009=\u200939) and <jats:italic>Staphylococcus aureus<\/jats:italic> (<jats:italic>n<\/jats:italic>\u2009=\u200927) resistance transmission were most commonly modelled, focusing on multi-drug and methicillin resistance, respectively. Forty-one studies examined multiple interventions, predominantly drug therapy and vaccination, showing an increasing trend. Most studies were population-based compartmental models (<jats:italic>n<\/jats:italic>\u2009=\u2009112). The TRACE framework was applied to 39 studies, showing a general lack of description of test and verification of modelling software and comparison of model outputs with external data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Despite efforts to model antimicrobial resistance and prevention strategies, significant gaps in scope, geographical coverage, drug-pathogen combinations, and viral-bacterial dynamics persist, along with inadequate documentation, hindering model updates and consistent outcomes for policymakers. This review highlights the need for robust modelling practices to enable model refinement as new data becomes available. Particularly, new data for validating modelling outcomes should be a focal point in future modelling research.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13756-025-01574-x","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T21:40:13Z","timestamp":1748468413000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The neglected model validation of antimicrobial resistance transmission models \u2013 a systematic review"],"prefix":"10.1186","volume":"14","author":[{"given":"Maja L.","family":"Brinch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Palladino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Geurtsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Van Effelterre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Argante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"McConnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Pihl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasja K.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine","family":"Hald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"1574_CR1","unstructured":"World Health Organisation. Ten threats to global health in 2019. 2019 [cited 2021 Sep 23]. Available from: https:\/\/www.who.int\/news-room\/spotlight\/ten-threats-to-global-health-in-2019"},{"key":"1574_CR2","unstructured":"O\u2019Neill J. Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. 2014."},{"key":"1574_CR3","unstructured":"Murray CJ, Shunji Ikuta K, Sharara F, Swetschinski L, Robles Aguilar G, Gray A et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022 Jan [cited 2022 Jan 26];399(10325):619\u201355. Available from: http:\/\/www.thelancet.com\/article\/S0140673621027240\/fulltext"},{"key":"1574_CR4","unstructured":"European Antimicrobial Resistance Collaborators, Mestrovic T, Robles Aguilar G, Swetschinski LR, Ikuta KS, Gray AP et al. The burden of bacterial antimicrobial resistance in the WHO European region in 2019: a cross-country systematic analysis. Lancet Public Health. 2022 Nov 1 [cited 2023 Dec 7];7(11):e897\u2013913. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36244350\/"},{"key":"1574_CR5","unstructured":"Ventola CL. The Antibiotic Resistance Crisis: Part 1: Causes and Threats. Pharmacy and Therapeutics. 2015 [cited 2021 Sep 29];40(4):277. Available from: \/pmc\/articles\/PMC4378521\/."},{"key":"1574_CR6","unstructured":"World Health Organization. Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance. 2021."},{"key":"1574_CR7","unstructured":"World Health Organization. Estimating the impact of vaccines in reducing antimicrobial resistance and antibiotic use: technical report. Geneva; 2024."},{"issue":"5","key":"1574_CR8","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.drudis.2019.03.002","volume":"24","author":"MJ McConnell","year":"2019","unstructured":"McConnell MJ. Where are we with monoclonal antibodies for multidrug-resistant infections? Drug Discov Today. 2019;24(5):1132\u20138.","journal-title":"Drug Discov Today"},{"key":"1574_CR9","doi-asserted-by":"crossref","unstructured":"Troisi M, Marini E, Abbiento V, Stazzoni S, Andreano E, Rappuoli R. A new dawn for monoclonal antibodies against antimicrobial resistant bacteria. Front Microbiol. 2022 Dec 14 [cited 2023 May 2];13. Available from: \/pmc\/articles\/PMC9795047\/.","DOI":"10.3389\/fmicb.2022.1080059"},{"key":"1574_CR10","doi-asserted-by":"crossref","unstructured":"Niewiadomska AM, Jayabalasingham B, Seidman JC, Willem L, Grenfell B, Spiro D et al. Population-level mathematical modeling of antimicrobial resistance: A systematic review. BMC Medicine BioMed Central Ltd.; Apr 24, 2019 p. 1\u201320. Available from: \/articles\/journal_contribution\/Additional_file_1_of_Population-level_mathematical_modeling_of_antimicrobial_resistance_a_systematic_review\/8032790\/1.","DOI":"10.1186\/s12916-019-1314-9"},{"issue":"6","key":"1574_CR11","doi-asserted-by":"publisher","first-page":"e204","DOI":"10.1016\/S1473-3099(17)30478-4","volume":"18","author":"KE Atkins","year":"2018","unstructured":"Atkins KE, Lafferty EI, Deeny SR, Davies NG, Robotham JV, Jit M. Use of mathematical modelling to assess the impact of vaccines on antibiotic resistance. Lancet Infect Dis. 2018;18(6):e204\u201313.","journal-title":"Lancet Infect Dis"},{"key":"1574_CR12","doi-asserted-by":"crossref","unstructured":"Birkeg\u00e5rd AC, Halasa T, Toft N, Folkesson A, Gr\u00e6sb\u00f8ll K. Send more data: a systematic review of mathematical models of antimicrobial resistance. Antimicrob Resist Infect Control. 2018 Sep 29 [cited 2021 Oct 12];7(1). Available from: \/pmc\/articles\/PMC6162961\/.","DOI":"10.1186\/s13756-018-0406-1"},{"key":"1574_CR13","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ecolmodel.2014.01.018","volume":"280","author":"V Grimm","year":"2014","unstructured":"Grimm V, Augusiak J, Focks A, Frank BM, Gabsi F, Johnston ASA, et al. Towards better modelling and decision support: documenting model development, testing, and analysis using TRACE. Ecol Modell. 2014;280:129\u201339.","journal-title":"Ecol Modell"},{"key":"1574_CR14","doi-asserted-by":"crossref","unstructured":"Falsey AR, Becker KL, Swinburne AJ, Nylen ES, Formica MA, Hennessey PA et al. Bacterial Complications of Respiratory Tract Viral Illness: A Comprehensive Evaluation. J Infect Dis. 2013 Aug 8 [cited 2024 Aug 7];208(3):432. Available from: \/pmc\/articles\/PMC3699009\/.","DOI":"10.1093\/infdis\/jit190"},{"key":"1574_CR15","doi-asserted-by":"crossref","unstructured":"Rowe HM, Meliopoulos VA, Iverson A, Bomme P, Schultz-Cherry S, Rosch JW. Direct interactions with influenza promote bacterial adherence during respiratory infections. Nat Microbiol. 2019 Aug 1 [cited 2024 Aug 7];4(8):1328. Available from: \/pmc\/articles\/PMC7069060\/.","DOI":"10.1038\/s41564-019-0447-0"},{"key":"1574_CR16","volume-title":"Review on antimicrobial resistance antimicrobial resistance: tackling a crisis for the health and wealth of nations","author":"J O\u2019Neill","year":"2016","unstructured":"O\u2019Neill J. Review on antimicrobial resistance antimicrobial resistance: tackling a crisis for the health and wealth of nations. London: Review on Antimicrobial Resistance; 2016."},{"issue":"10","key":"1574_CR17","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jclinepi.2009.06.005","volume":"62","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006\u201312.","journal-title":"J Clin Epidemiol"},{"key":"1574_CR18","unstructured":"Veritas Health Innovation. Covidence systematic review software. Melbourne, Australia. 2022. Available from: www.covidence.org."},{"key":"1574_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijid.2019.05.005","volume":"85","author":"CE Barnes","year":"2019","unstructured":"Barnes CE, MacIntyre CR. Risk modelling the mortality impact of antimicrobial resistance in secondary Pneumococcal pneumonia infections during the 2009 influenza pandemic. Int J Infect Dis. 2019;85:1\u20136.","journal-title":"Int J Infect Dis"},{"key":"1574_CR20","doi-asserted-by":"crossref","unstructured":"Almagor J, Temkin E, Benenson I, Fallach N, Carmeli Y. The impact of antibiotic use on transmission of resistant bacteria in hospitals: insights from an agent-based model. PLoS ONE. 2018;13(5).","DOI":"10.1371\/journal.pone.0197111"},{"issue":"11","key":"1574_CR21","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1128\/JCM.00635-16","volume":"54","author":"SM Bartsch","year":"2016","unstructured":"Bartsch SM, Huang SS, Wong KF, Slayton RB, McKinnell JA, Sahm DF, et al. Impact of delays between clinical and laboratory standards Institute and food and drug administration revisions of interpretive criteria for carbapenem-resistant Enterobacteriaceae. J Clin Microbiol. 2016;54(11):2757\u201362.","journal-title":"J Clin Microbiol"},{"issue":"6\u20137","key":"1574_CR22","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00285-017-1128-3","volume":"75","author":"X Cen","year":"2017","unstructured":"Cen X, Feng Z, Zheng Y, Zhao Y. Bifurcation analysis and global dynamics of a mathematical model of antibiotic resistance in hospitals. J Math Biol. 2017;75(6\u20137):1463\u201385.","journal-title":"J Math Biol"},{"issue":"5","key":"1574_CR23","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.4269\/ajtmh.18-0930","volume":"101","author":"HH Chen","year":"2019","unstructured":"Chen HH, Stringer A, Eguale T, Rao GG, Ozawa S. Impact of antibiotic resistance on treatment of Pneumococcal disease in Ethiopia: an Agent-Based modeling simulation. Am J Trop Med Hyg. 2019;101(5):1042\u201353.","journal-title":"Am J Trop Med Hyg"},{"key":"1574_CR24","doi-asserted-by":"crossref","unstructured":"Cilloni L, Kranzer K, Stagg HR, Arinaminpathy N. Trade-offs between cost and accuracy in active case finding for tuberculosis: A dynamic modelling analysis. PLoS Med. 2020;17(12).","DOI":"10.1371\/journal.pmed.1003456"},{"issue":"3","key":"1574_CR25","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41564-019-0651-y","volume":"5","author":"C Colijn","year":"2020","unstructured":"Colijn C, Corander J, Croucher NJ. Designing ecologically optimized Pneumococcal vaccines using population genomics. Nat Microbiol. 2020;5(3):473\u201385.","journal-title":"Nat Microbiol"},{"issue":"12","key":"1574_CR26","first-page":"3366","volume":"70","author":"SR Deeny","year":"2015","unstructured":"Deeny SR, Worby CJ, Tosas Auguet O, Cooper BS, Edgeworth J, Cookson B, et al. Impact of mupirocin resistance on the transmission and control of healthcare-associated MRSA. J Antimicrob Chemother. 2015;70(12):3366\u201378.","journal-title":"J Antimicrob Chemother"},{"issue":"29","key":"1574_CR27","doi-asserted-by":"publisher","first-page":"14599","DOI":"10.1073\/pnas.1900959116","volume":"116","author":"F Ruscio","year":"2019","unstructured":"Ruscio F, Di, Guzzetta G, Bj\u00f8rnholt JV, Leegaard TM, Moen AEF, Merler S, et al. Quantifying the transmission dynamics of MRSA in the community and healthcare settings in a low-prevalence country. Proc Natl Acad Sci U S A. 2019;116(29):14599\u2013605.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1574_CR28","doi-asserted-by":"crossref","unstructured":"Duan Q, Carmody C, Donovan B, Guy RJ, Hui BB, Kaldor JM et al. Modelling response strategies for controlling gonorrhoea outbreaks in men who have sex with men in Australia. PLoS Comput Biol. 2021;17(11).","DOI":"10.1371\/journal.pcbi.1009385"},{"key":"1574_CR29","doi-asserted-by":"crossref","unstructured":"Fu H, Lewnard JA, Frost I, Laxminarayan R, Arinaminpathy N. Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine. Nat Commun. 2021;12(1).","DOI":"10.1038\/s41467-020-20731-x"},{"key":"1574_CR30","doi-asserted-by":"crossref","unstructured":"Han WM, Mahikul W, Pouplin T, Lawpoolsri S, White LJ, Pan-Ngum W. Assessing the impacts of short-course multidrug-resistant tuberculosis treatment in the Southeast Asia region using a mathematical modeling approach. PLoS ONE. 2021;16(3).","DOI":"10.1371\/journal.pone.0248846"},{"issue":"1","key":"1574_CR31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jhin.2017.03.011","volume":"96","author":"AD Harris","year":"2017","unstructured":"Harris AD, Morgan DJ, Pineles L, Perencevich EN, Barnes SL. Deconstructing the relative benefits of a universal glove and gown intervention on MRSA acquisition. J Hosp Infect. 2017;96(1):49\u201353.","journal-title":"J Hosp Infect"},{"key":"1574_CR32","doi-asserted-by":"crossref","unstructured":"Ho Kwai, Ng W tong, Ip M, You JHS. Active surveillance of carbapenem-resistant Enterobacteriaceae in intensive care units: Is it cost-effective in a nonendemic region? Am J Infect Control. 2016;44(4):394\u20139.","DOI":"10.1016\/j.ajic.2015.10.026"},{"issue":"3","key":"1574_CR33","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1017\/S0950268813001106","volume":"142","author":"C Hogea","year":"2014","unstructured":"Hogea C, Van Effelterre T, Acosta CJ. A basic dynamic transmission model of Staphylococcus aureus in the US population. Epidemiol Infect. 2014;142(3):468\u201378.","journal-title":"Epidemiol Infect"},{"key":"1574_CR34","doi-asserted-by":"crossref","unstructured":"Hughes J, Huo X, Falk L, Hurford A, Lan K, Coburn B et al. Benefits and unintended consequences of antimicrobial de-escalation: implications for stewardship programs. PLoS ONE. 2017;12(2).","DOI":"10.1371\/journal.pone.0171218"},{"key":"1574_CR35","doi-asserted-by":"crossref","unstructured":"Kachalov VN, Nguyen H, Balakrishna S, Salazar-Vizcaya L, Sommerstein R, Kuster SP et al. Identifying the drivers of multidrug-resistant Klebsiella pneumoniae at a European level. PLoS Comput Biol. 2021;17(1).","DOI":"10.1371\/journal.pcbi.1008446"},{"key":"1574_CR36","doi-asserted-by":"crossref","unstructured":"Karda\u015b-S\u0142oma L, Lucet JC, Perozziello A, Pelat C, Birgand G, Rupp\u00e9 E et al. Universal or targeted approach to prevent the transmission of extended-spectrum beta-lactamase-producing Enterobacteriaceae in intensive care units: A cost-effectiveness analysis. BMJ Open. 2017;7(11).","DOI":"10.1136\/bmjopen-2017-017402"},{"key":"1574_CR37","doi-asserted-by":"crossref","unstructured":"Laager M, Cooper BS, Eyre DW. Probabilistic modelling of effects of antibiotics and calendar time on transmission of healthcare-associated infection. Scientific Reports 2021 11:1. 2021;11(1):1\u201311.","DOI":"10.1038\/s41598-021-00748-y"},{"issue":"8","key":"1574_CR38","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ajic.2013.01.013","volume":"41","author":"BY Lee","year":"2013","unstructured":"Lee BY, Yilmaz SL, Wong KF, Bartsch SM, Eubank S, Song Y, et al. Modeling the regional spread and control of vancomycin-resistant enterococci. Am J Infect Control. 2013;41(8):668\u201373.","journal-title":"Am J Infect Control"},{"issue":"5","key":"1574_CR39","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/aje\/kwv299","volume":"183","author":"BY Lee","year":"2016","unstructured":"Lee BY, Bartsch SM, Wong KF, McKinnell JA, Slayton RB, Miller LG, et al. The potential trajectory of Carbapenem-Resistant enterobacteriaceae, an emerging threat to Health-Care facilities, and the impact of the centers for disease control and prevention toolkit. Am J Epidemiol. 2016;183(5):471\u20139.","journal-title":"Am J Epidemiol"},{"key":"1574_CR40","doi-asserted-by":"crossref","unstructured":"Liao CM, Lin YJ. Assessing the transmission risk of multidrug-resistant Mycobacterium tuberculosis epidemics in regions of Taiwan. Int J Infect Dis. 2012;16(10).","DOI":"10.1016\/j.ijid.2012.06.001"},{"issue":"8","key":"1574_CR41","doi-asserted-by":"publisher","first-page":"e1005704","DOI":"10.1371\/journal.pcbi.1005704","volume":"13","author":"JI Liechti","year":"2017","unstructured":"Liechti JI, Leventhal GE, Bonhoeffer S. Host population structure impedes reversion to drug sensitivity after discontinuation of treatment. PLoS Comput Biol. 2017;13(8):e1005704.","journal-title":"PLoS Comput Biol"},{"issue":"4","key":"1574_CR42","first-page":"1","volume":"8","author":"A Machlaurin","year":"2020","unstructured":"Machlaurin A, Dolk FCK, Setiawan D, van der Werf TS, Postma MJ. Cost-Effectiveness analysis of BCG vaccination against tuberculosis in Indonesia: A Model-Based study. Vaccines (Basel). 2020;8(4):1\u201314.","journal-title":"Vaccines (Basel)"},{"issue":"9","key":"1574_CR43","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1093\/aje\/kwy094","volume":"187","author":"NA Menzies","year":"2018","unstructured":"Menzies NA, Cohen T, Hill AN, Yaesoubi R, Galer K, Wolf E, et al. Prospects for tuberculosis elimination in the united States: results of a transmission dynamic model. Am J Epidemiol. 2018;187(9):2011\u201320.","journal-title":"Am J Epidemiol"},{"issue":"2","key":"1574_CR44","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/jac\/dkab398","volume":"77","author":"K Mponponsuo","year":"2022","unstructured":"Mponponsuo K, Leal J, Spackman E, Somayaji R, Gregson D, Rennert-May E. Mathematical model of the cost-effectiveness of the biofire filmarray blood culture identification (BCID) panel molecular rapid diagnostic test compared with conventional methods for identification of Escherichia coli bloodstream infections. J Antimicrob Chemother. 2022;77(2):507\u201316.","journal-title":"J Antimicrob Chemother"},{"issue":"10325","key":"1574_CR45","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"CJ Murray","year":"2022","unstructured":"Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629\u201355.","journal-title":"Lancet"},{"issue":"8","key":"1574_CR46","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1111\/risa.13618","volume":"41","author":"L Opatowski","year":"2021","unstructured":"Opatowski L, Opatowski M, Vong S, Temime L. A One-Health quantitative model to assess the risk of antibiotic resistance acquisition in Asian populations: impact of exposure through food, water, livestock and humans. Risk Anal. 2021;41(8):1427\u201346.","journal-title":"Risk Anal"},{"issue":"45","key":"1574_CR47","doi-asserted-by":"publisher","first-page":"6700","DOI":"10.1016\/j.vaccine.2021.04.024","volume":"39","author":"S Ozawa","year":"2021","unstructured":"Ozawa S, Chen HH, Rao GG, Eguale T, Stringer A. Value of Pneumococcal vaccination in controlling the development of antimicrobial resistance (AMR): case study using DREAMR in Ethiopia. Vaccine. 2021;39(45):6700\u201311.","journal-title":"Vaccine"},{"issue":"4","key":"1574_CR48","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jbi.2010.03.013","volume":"43","author":"SS Panchanathan","year":"2010","unstructured":"Panchanathan SS, Petitti DB, Fridsma DB. The development and validation of a simulation tool for health policy decision making. J Biomed Inf. 2010;43(4):602\u20137.","journal-title":"J Biomed Inf"},{"key":"1574_CR49","doi-asserted-by":"crossref","unstructured":"Pe\u010derska J, K\u00fchnert D, Meehan CJ, Coscoll\u00e1 M, de Jong BC, Gagneux S et al. Quantifying transmission fitness costs of multi-drug resistant tuberculosis. Epidemics. 2021;36.","DOI":"10.1016\/j.epidem.2021.100471"},{"key":"1574_CR50","doi-asserted-by":"crossref","unstructured":"Suen SC, Bendavid E, Goldhaber-Fiebert JD. Disease control implications of India\u2019s changing multi-drug resistant tuberculosis epidemic. PLoS ONE. 2014;9(3).","DOI":"10.1371\/journal.pone.0089822"},{"key":"1574_CR51","doi-asserted-by":"crossref","unstructured":"Suthar N, Roy S, Call DR, Besser TE, Davis MA. An individual-based model of transmission of resistant bacteria in a veterinary teaching hospital. PLoS ONE. 2014;9(6).","DOI":"10.1371\/journal.pone.0098589"},{"issue":"9","key":"1574_CR52","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1017\/S0950268816000030","volume":"144","author":"A Talaminos","year":"2016","unstructured":"Talaminos A, L\u00f3pez-Cerero L, Calvillo J, Pascual A, Roa LM, Rodr\u00edguez-Ba\u00f1o J. Modelling the epidemiology of Escherichia coli ST131 and the impact of interventions on the community and healthcare centres. Epidemiol Infect. 2016;144(9):1974\u201382.","journal-title":"Epidemiol Infect"},{"issue":"Suppl 1","key":"1574_CR53","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1093\/cid\/ciaa1590","volume":"72","author":"DJA Toth","year":"2021","unstructured":"Toth DJA, Samore MH, Nelson RE. Economic evaluations of new antibiotics: the high potential value of reducing healthcare transmission through decolonization. Clin Infect Dis. 2021;72(Suppl 1):S34\u201341.","journal-title":"Clin Infect Dis"},{"key":"1574_CR54","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.epidem.2018.11.001","volume":"26","author":"TN Vilches","year":"2019","unstructured":"Vilches TN, Bonesso MF, Guerra HM, Fortaleza CMCB, Park AW, Ferreira CP. The role of intra and inter-hospital patient transfer in the dissemination of heathcare-associated multidrug-resistant pathogens. Epidemics. 2019;26:104\u201315.","journal-title":"Epidemics"},{"key":"1574_CR55","doi-asserted-by":"crossref","unstructured":"Wang X, Panchanathan S, Chowell GA, Data-Driven. Mathematical model of CA-MRSA transmission among age groups: evaluating the effect of control interventions. PLoS Comput Biol. 2013;9(11).","DOI":"10.1371\/journal.pcbi.1003328"},{"key":"1574_CR56","doi-asserted-by":"crossref","unstructured":"Weerasuriya CK, Harris RC, McQuaid CF, Bozzani F, Ruan Y, Li R et al. The epidemiologic impact and cost-effectiveness of new tuberculosis vaccines on multidrug-resistant tuberculosis in India and China. BMC Med. 2021;19(1).","DOI":"10.1186\/s12916-021-01932-7"},{"issue":"2","key":"1574_CR57","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1080\/17513758.2012.670733","volume":"6","author":"M Yahdi","year":"2012","unstructured":"Yahdi M, Abdelmageed S, Lowden J, Tannenbaum L. Vancomycin-resistant enterococci colonization-infection model: parameter impacts and outbreak risks. J Biol Dyn. 2012;6(2):645\u201362.","journal-title":"J Biol Dyn"},{"key":"1574_CR58","doi-asserted-by":"crossref","unstructured":"Zacher B, Haller S, Willrich N, Walter J, Sin MA, Cassini A et al. Application of a new methodology and R package reveals a high burden of healthcare-associated infections (HAI) in Germany compared to the average in the European Union\/European economic area, 2011 to 2012. Eurosurveillance. 2019;24(46).","DOI":"10.2807\/1560-7917.ES.2019.24.46.1900135"},{"issue":"10325","key":"1574_CR59","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"AR Collaborators","year":"2022","unstructured":"Collaborators AR, Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629\u201355.","journal-title":"Lancet"},{"key":"1574_CR60","unstructured":"Hendriksen RS, Munk P, Njage P, van Bunnik B, McNally L, Lukjancenko O et al. Global monitoring of antimicrobial resistance based on metagenomics analyses of urban sewage. Nat Commun. 2019;10(1)."},{"key":"1574_CR61","unstructured":"Munk P, Brinch C, M\u00f8ller FD, Petersen TN, Hendriksen RS, Seyfarth AM et al. Genomic analysis of sewage from 101 countries reveals global landscape of antimicrobial resistance. Nat Commun. 2022;13(1)."},{"issue":"3","key":"1574_CR62","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318\u201327.","journal-title":"Lancet Infect Dis"},{"key":"1574_CR63","unstructured":"World Health Organization. Implementing the end TB strategy: the essentials, 2022 update. Geneva; 2022."},{"key":"1574_CR64","doi-asserted-by":"crossref","unstructured":"Nadimpalli ML, Marks SJ, Montealegre MC, Gilman RH, Pajuelo MJ, Saito M et al. Urban informal settlements as hotspots of antimicrobial resistance and the need to curb environmental transmission. 5, Nat Microbiol. 2020.","DOI":"10.1038\/s41564-020-0722-0"},{"key":"1574_CR65","doi-asserted-by":"crossref","unstructured":"Koupaei M, Asadi A, Mahdizade Ari M, Seyyedi ZS, Mohammadi F, Afifi rad R, et al. Secondary Klebsiella pneumoniae infection in patients with COVID-19: A systematic review. Volume 108. Diagnostic Microbiology and Infectious Disease; 2024.","DOI":"10.1016\/j.diagmicrobio.2023.116105"},{"key":"1574_CR66","doi-asserted-by":"crossref","unstructured":"Morris DE, Cleary DW, Clarke SC. Secondary bacterial infections associated with influenza pandemics. 8, Front Microbiol. 2017.","DOI":"10.3389\/fmicb.2017.01041"},{"key":"1574_CR67","doi-asserted-by":"crossref","unstructured":"Lee WC, Ho MC, Leu SW, Chang CC, Lin CK, Lin CM et al. The impacts of bacterial co-infections and secondary bacterial infections on patients with severe influenza pneumonitis admitted to the intensive care units. J Crit Care. 2022;72.","DOI":"10.1016\/j.jcrc.2022.154164"},{"key":"1574_CR68","doi-asserted-by":"crossref","unstructured":"Yano TK, Afrifa-Yamoah E, Collins J, Mueller U, Richardson S. Mathematical modelling and analysis for the co-infection of viral and bacterial diseases: a systematic review protocol. BMJ Open. 2024;14(12):e084027. Available from: http:\/\/bmjopen.bmj.com\/content\/14\/12\/e084027.abstract","DOI":"10.1136\/bmjopen-2024-084027"},{"key":"1574_CR69","unstructured":"World Health Organization. WHO methods and data sources Estimates, for global burden of disease 2000\u20132019. 2020 [cited 2023 May 3]. Available from: http:\/\/www.who.int\/gho\/mortality_burden_disease\/en\/index.html"},{"key":"1574_CR70","unstructured":"World Health Organization. Global action plan on antimicrobial resistance. WHO; 2015."},{"key":"1574_CR71","unstructured":"World Health Organization. Immunization Agenda 2030: A Global Strategy To Leave No One Behind. 2020."},{"key":"1574_CR72","doi-asserted-by":"crossref","unstructured":"Vekemans J, Hasso-Agopsowicz M, Kang G, Hausdorff WP, Fiore A, Tayler E et al. Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance: A World Health Organization Action Framework. Clinical Infectious Diseases. 2021 Aug 16 [cited 2023 May 2];73(4):e1011\u20137. Available from: https:\/\/academic.oup.com\/cid\/article\/73\/4\/e1011\/6119610","DOI":"10.1093\/cid\/ciab062"},{"key":"1574_CR73","doi-asserted-by":"publisher","unstructured":"Frost I, Balachandran A, Paulin-Deschenaux S, Sati H, Hasso-Agopsowicz M. The approach of World Health Organization to articulate the role and assure impact of vaccines against antimicrobial resistance. Hum Vaccin Immunother. 2022 [cited 2023 May 2];18(6). Available from: https:\/\/doi.org\/10.1080\/21645515.2022.2145069","DOI":"10.1080\/21645515.2022.2145069"},{"key":"1574_CR74","doi-asserted-by":"crossref","unstructured":"Kim C, Holm M, Frost I, Hasso-Agopsowicz M, Abbas K. Global and regional burden of attributable and associated bacterial antimicrobial resistance avertable by vaccination: modelling study. BMJ Glob Health. 2023 Jul 6 [cited 2023 Aug 18];8(7):e011341. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37414432\/","DOI":"10.1136\/bmjgh-2022-011341"},{"key":"1574_CR75","unstructured":"WHO, OIE FAO. UNEP. Strategic framework for collaboration on antimicrobial resistance \u2013 together for One Health. Geneva; 2022."}],"container-title":["Antimicrobial Resistance &amp; Infection Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-025-01574-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13756-025-01574-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13756-025-01574-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T21:40:34Z","timestamp":1748468434000},"score":1,"resource":{"primary":{"URL":"https:\/\/aricjournal.biomedcentral.com\/articles\/10.1186\/s13756-025-01574-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1574"],"URL":"https:\/\/doi.org\/10.1186\/s13756-025-01574-x","relation":{},"ISSN":["2047-2994"],"issn-type":[{"value":"2047-2994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"14 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AP and LA are employees of GSK. JG is currently an employee of Sanofi. At the moment this work was conducted, JG was an employee of Janssen Vaccines & Prevention B.V. and a holder of Johnson & Johnson stock options. TE is an employee of Johnson & Johnson and is a Johnson & Johnson stockholder. MJM is a confounder, stockholder, and has received financial support from the biotechnology company Vaxdyn. Vaxdyn played no role in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"59"}}